Genentech, a leading biotechnology company, has announced an update on its Phase II/III SKYSCRAPER-06 study, which is investigating the efficacy of tiragolumab in combination with atezolizumab and chemotherapy for the treatment of metastatic non-squamous non-small cell lung cancer (NSCLC). The study did not meet its co-primary endpoint of progression-free survival, and the company is currently evaluating the implications of these results.
Despite the setback in the SKYSCRAPER-06 study, Genentech remains committed to exploring the potential of tiragolumab in other ongoing Phase III studies, which are focused on distinct treatment settings and indications. The company plans to assess the need for any relevant changes to the tiragolumab program based on the findings from the SKYSCRAPER-06 study.
